Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

By Jocelyn Solis-MoreiraMay 3 2021

Most treatment and vaccine development have been focused on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. This is chiefly because the spike is the viral protein that mediates SARS-CoV-2's entry into the host cell.

However, evolving variants have been associated with important mutations in viral spike proteins that could allow them to escape immune responses elicited from both vaccines and natural infection. Developing multivalent prophylactics and therapeutics will thus be crucial in ensuring long-term management of the coronavirus disease 2019 (COVID-19) pandemic.

Study: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. Image Credit: Juan Gaertner / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

New preclinical results from a study led by David Masopust of the University of Minnesota in Minneapolis, USA, show that a Had5-based vaccine targeting the nucleocapsid protein can also elicit a protective immune response.

The authors write:

We show that vaccination with HAd5 expressing the nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and k18-hACE2 mice.”

The results emphasize the importance of memory T cells in providing broad immunity against SARS-CoV-2. They suggest memory T cell immunity could inform future vaccine development to overcome any emerging variants that can successfully evade neutralizing antibodies.

The study “Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity” is available as a preprint on the bioRxiv* server, while the article undergoes peer review.

Vaccine protects against weight loss and death

The researcher used an adenovirus to express the nucleocapsid protein. They gave an intravenous injection of the human adenovirus serotype 5 vector or a control adenovirus, which lacked the SARS-CoV-2 strain into Syrian hamsters. After 7 to 8 weeks, the animals had an intranasal challenge with the WA SARS-CoV-2 strain.

They evaluated vaccine-induced immunity through viral titer levels and T cell responses. They reasoned T cells would be useful in mounting a robust immune response given that T cell immunity is less vulnerable to immune selection pressure and immune evasion from SARS-CoV-2 spike protein mutations.

Results from Syrian hamsters found the nucleocapsid vaccine provided protection from COVID-19 infection and prevented weight loss from infection.

Vaccinated hamsters were then challenged with the WA strain or the B.1.1.7 variant. The team found a reduction in lung virus titers of vaccinated hamsters. Specifically, there was a 30-fold reduction with the WA strain and a 12-fold reduction in virus titers with the B.1.1.7 strain three days after exposure.

Transgenic K18-hACEC2 mice models were also tested and found vaccination helped with reducing weight loss and mortality. About 75% of mice who were vaccinated survived exposure to the WA SARS-CoV-2 challenge — no one from the control group survived.

Role of memory T cells in vaccine-induced immunity

The nucleocapsid vaccine created CD8 memory T cells specific to SARS-CoV-2. These cells continued to be present in the lungs, airways, and spleen from 40 to 86 days and increased in lung draining mediastinal lymph node.

The researchers also found memory T cells important in the immune response after a viral challenge. Vaccinated mice showed approximately a 3.8-log10 reduction in lung viral loads.

Lowering the amounts of CD4s and CD8bs showed a reduction in viral load, which correlated with SARS-specific CD8 T cell numbers in the lungs.

Exposure to SARS-CoV-2 increased granzyme B+ N_219-227-specific CD8 T cells in the mucus membrane of the respiratory tract. There was also an increase in the total number of N_219-227-specific CD8 T cells in the lung parenchyma and the draining mediastinal lymph node.

These data indicate that vaccine-elicited memory CD8 T cells underwent rapid reactivation and migration to the site of viral challenge, and that T cells may have contributed to viral control.”

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources